Date: 2015-01-12
Type of information: Private placement
Company: Capricor Therapeutics (USA - CA)
Investors: CureDuchenne Ventures (USA - CA)
Amount: $1 million
Funding type: private placement
Planned used: Capricor has shown positive pre-clinical data for Cardiosphere-derived cells (CDCs) on Duchenne muscular dystrophy cardiomyopathy. CureDuchenne is investing in Capricor to support the conduct of a phase I clinical trial in patients with Duchenne. The planned trial would use CAP-1002 cardiosphere-derived cells delivered to the heart. The goal is to improve global cardiac function, decrease fibrosis, improve exercise capacity, and reverse abnormalities in mitochondrial abundance, structure and function. The investigational therapy is an allogeneic, off-the-shelf “ready to use” cell therapy which comes from donor heart tissue and is infused directly into a patient’s coronary artery during a catheterization procedure. CAP-1002 is being tested to determine if it is safe and effective in impacting heart function and structure in patients who have had a myocardial infarction.
Others: * On January 12, 2015, CureDuchenne Ventures LLC announced that they are investing $1 million in Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, to advance promising research to treat heart disease associated with Duchenne muscular dystrophy. Capricor has shown positive pre-clinical data for Cardiosphere-derived cells (CDCs) on Duchenne muscular dystrophy cardiomyopathy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national non-profit that has funded seven research projects that have advanced to human clinical trials. CureDuchenne has leveraged $100 million in pharma and biotech research and development investments. Now three of the projects CureDuchenne supported with funding, Prosensa Holding N.V., Sarepta Therapeutics and PTC Therapeutics, are the closest to becoming the first drugs to be approved for the treatment of the disorder.
Therapeutic area: Rare diseases - Neuromuscular diseases
